Three separate experimental approaches were used above to demonstrate ADMC, and mediators from FcεRI-challenged ADMC, have anti-tumor activity and suggests the possibility of using autologous (or allogeneic) MC in cancer immunotherapy. This evidence concerns the gene FCER1A and neoplasm.